Icatibant Hikma

Icatibant, the active ingredient in Icatibant Hikma, is a Bradykinin B2 receptor antagonist presented as an injection for intravenous use. It treats hereditary angioedema attacks in patients with a confirmed diagnosis.

GNH USA supplies Icatibant Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema, acting on the bradykinin pathway to relieve acute swelling.

Hereditary angioedema attacks: provides rapid reduction of edema and associated pain during an acute episode.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema - Headache - Nausea or vomiting - Dizziness or light‑headedness - Flushing - Fatigue

Serious or Rare Side Effects: - Severe hypersensitivity or anaphylaxis - Angioedema unrelated to hereditary disease - Urticaria or rash - Significant hypotension - Necrotic skin reactions at injection site - Pulmonary edema

Before using Icatibant, consider the following safety measures. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown effects; weigh benefits against possible infant exposure. - Renal impairment: no specific dose adjustment, but monitor renal function. - Concomitant ACE inhibitors or neprilysin inhibitors: may increase bradykinin levels; observe for enhanced edema. - Known hypersensitivity: discontinue immediately if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence bradykinin or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin‑mediated effects, increasing risk of angioedema. - Neprilysin inhibitors (e.g., sacubitril): elevate bradykinin levels, heightening adverse event potential. - Other bradykinin B2 antagonists: additive pharmacodynamic effects.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal irritation. - Estrogen‑containing contraceptives: possible increase in bradykinin activity. - Diuretics: monitor blood pressure and electrolyte balance. - Antihistamines: may mask early signs of hypersensitivity. - Corticosteroids: assess for overlapping immunomodulatory effects.